Turning Point Therapeutics, Inc.

Informe acción NasdaqGS:TPTX

Capitalización de mercado: US$3.8b

Salud financiera de hoja de balance de Turning Point Therapeutics

Salud financiera controles de criterios 6/6

Turning Point Therapeutics tiene un patrimonio de los accionistas total de $793.0M y una deuda total de $0.0, lo que sitúa su ratio deuda-patrimonio en 0%. Sus activos y pasivos totales son $843.3M y $50.3M respectivamente.

Información clave

0%

Ratio deuda-patrimonio

US$0

Deuda

Ratio de cobertura de interesesn/a
EfectivoUS$818.29m
PatrimonioUS$793.02m
Total pasivoUS$50.31m
Activos totalesUS$843.34m

Actualizaciones recientes sobre salud financiera

Recent updates

Bristol Myers U.S., German antitrust filings for Turning Point expected very soon - report

Jul 21

We Think Turning Point Therapeutics (NASDAQ:TPTX) Can Afford To Drive Business Growth

Mar 23
We Think Turning Point Therapeutics (NASDAQ:TPTX) Can Afford To Drive Business Growth

Companies Like Turning Point Therapeutics (NASDAQ:TPTX) Are In A Position To Invest In Growth

Dec 06
Companies Like Turning Point Therapeutics (NASDAQ:TPTX) Are In A Position To Invest In Growth

The Take On Turning Point Therapeutics

Dec 03

Industry Analysts Just Made A Sizeable Upgrade To Their Turning Point Therapeutics, Inc. (NASDAQ:TPTX) Revenue Forecasts

Aug 15
Industry Analysts Just Made A Sizeable Upgrade To Their Turning Point Therapeutics, Inc. (NASDAQ:TPTX) Revenue Forecasts

Turning Point Therapeutics (NASDAQ:TPTX) Is In A Strong Position To Grow Its Business

Aug 04
Turning Point Therapeutics (NASDAQ:TPTX) Is In A Strong Position To Grow Its Business

Turning Point Therapeutics gets FDA orphan drug status for TPX-0022 in gastric cancer

Jun 17

Turning Point Therapeutics, Inc. (NASDAQ:TPTX) Just Reported First-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?

May 08
Turning Point Therapeutics, Inc. (NASDAQ:TPTX) Just Reported First-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?

Have Insiders Been Selling Turning Point Therapeutics, Inc. (NASDAQ:TPTX) Shares This Year?

Feb 26
Have Insiders Been Selling Turning Point Therapeutics, Inc. (NASDAQ:TPTX) Shares This Year?

Turning Point Therapeutics' repotrectinib shows promising results in lung cancer study

Jan 29

Analysts' Revenue Estimates For Turning Point Therapeutics, Inc. (NASDAQ:TPTX) Are Surging Higher

Jan 22
Analysts' Revenue Estimates For Turning Point Therapeutics, Inc. (NASDAQ:TPTX) Are Surging Higher

We're Not Worried About Turning Point Therapeutics' (NASDAQ:TPTX) Cash Burn

Jan 13
We're Not Worried About Turning Point Therapeutics' (NASDAQ:TPTX) Cash Burn

Turning Point Therapeutics: An Emerging Growth Story In TKI-Resistant Cancers

Dec 28

Is Turning Point Therapeutics, Inc. (NASDAQ:TPTX) Trading At A 48% Discount?

Dec 15
Is Turning Point Therapeutics, Inc. (NASDAQ:TPTX) Trading At A 48% Discount?

Turning Point Therapeutics' lead candidate nabs accelerated review for lung cancer

Dec 08

Turning Point Therapeutics EPS beats by $0.12, beats on revenue

Nov 12

Análisis de la situación financiera

Pasivos a corto plazo: Los activos a corto plazo ($831.7M) de TPTX superan a sus pasivos a corto plazo ($49.4M).

Pasivo a largo plazo: Los activos a corto plazo de TPTX ($831.7M) superan a sus pasivos a largo plazo ($890.0K).


Historial y análisis de deuda-patrimonio

Nivel de deuda: TPTX está libre de deudas.

Reducción de la deuda: TPTX no ha tenido ninguna deuda en los últimos 5 años.


Hoja de balance


Análisis de cash runway

En el caso de las empresas que de media han sido deficitarias en el pasado, evaluamos si tienen al menos 1 año de cash runway.

Cash runway estable: TPTX tiene suficiente cash runway para más de 3 años basándose en su flujo de caja libre actual.

Pronóstico de cash runway: TPTX dispone de suficiente cash runway para más de 3 años si el flujo de caja libre sigue reduciéndose a tasas históricas de 51.2% cada año


Descubre empresas con salud financiera